Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

359
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
359
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

142
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
142
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

297
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
297
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

219
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
219
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

316
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
316
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

271
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
271

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of Anti-Seizure Medications on Interictal Epileptiform Discharges in Focal Epilepsy.

Clinical EEG and neuroscience·2025
Same author

Mood and Anxiety Disorders and Suicidality in Patients With Newly Diagnosed Focal Epilepsy: An Analysis of a Complex Comorbidity.

Neurology·2025
Same author

A multicenter Phase II randomized, placebo-controlled single-blind trial with the SV2A ligand seletracetam in photosensitive epilepsy patients.

Epilepsy & behavior : E&B·2025
Same author

Detection challenges of temporal encephaloceles in epilepsy: A retrospective analysis.

Magnetic resonance imaging·2024
Same author

The Adverse Effects of Commonly Prescribed Antiseizure Medications in Adults With Newly Diagnosed Focal Epilepsy.

Neurology·2024
Same author

Patterns of antiseizure medication utilization in the Human Epilepsy Project.

Epilepsia·2023
Same journal

Key Considerations in Telestroke Program Management.

Continuum (Minneapolis, Minn.)·2026
Same journal

Neurology's Action Potential: Delivering on the Promise of Brain Health.

Continuum (Minneapolis, Minn.)·2026
Same journal

Erratum.

Continuum (Minneapolis, Minn.)·2026
Same journal

Management of Large Artery Atherosclerosis.

Continuum (Minneapolis, Minn.)·2026
Same journal

Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)·2026
Same journal

Stroke in Children and Younger Adults.

Continuum (Minneapolis, Minn.)·2026
See all related articles

Related Experiment Video

Updated: May 29, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.0K

Update on Antiseizure Medications 2025.

Bassel W Abou-Khalil

    Continuum (Minneapolis, Minn.)
    |February 3, 2025
    PubMed
    Summary
    This summary is machine-generated.

    This updated review covers antiseizure medications for epilepsy management. Newer drugs offer comparable or better efficacy and tolerability than older options, guiding optimal treatment choices.

    More Related Videos

    Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue
    06:45

    Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue

    Published on: January 19, 2019

    8.9K
    Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
    09:07

    Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

    Published on: August 15, 2017

    12.0K

    Related Experiment Videos

    Last Updated: May 29, 2025

    Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
    07:01

    Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

    Published on: May 16, 2019

    9.0K
    Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue
    06:45

    Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue

    Published on: January 19, 2019

    8.9K
    Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
    09:07

    Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

    Published on: August 15, 2017

    12.0K

    Area of Science:

    • Neurology
    • Pharmacology

    Background:

    • This article updates previous reviews on antiseizure medication (ASM) therapy for epilepsy.
    • It covers a wide range of ASMs available for managing patients with epilepsy.

    Purpose of the Study:

    • To provide an overview of currently available ASMs, detailing their pharmacokinetic properties, indications, and usage.
    • To highlight recent FDA approvals and expanded indications for ASMs.

    Main Methods:

    • Individual review of ASMs, focusing on pharmacokinetics, efficacy, and tolerability.
    • Comparison of newer ASMs with older agents in clinical trials.

    Main Results:

    • Newer ASMs like lamotrigine, oxcarbazepine, levetiracetam, topiramate, zonisamide, and lacosamide show equal or superior efficacy and tolerability for focal epilepsy compared to older drugs.
    • Ganaxolone is a newly approved ASM.
    • Lacosamide, pregabalin, and eslicarbazepine are effective for conversion to monotherapy in focal epilepsy.

    Conclusions:

    • Understanding ASM pharmacokinetics, efficacy, and tolerability is crucial for selecting appropriate epilepsy treatments.
    • Rational ASM combinations should minimize pharmacokinetic and pharmacodynamic interactions.